OLA Blog

RELAPSE OF IMN AFTER TRANSPLANTATION

Written by Meguid El Nahas on Tuesday, 02 September 2014. Posted in OLA Blog

RELAPSE OF IMN AFTER TRANSPLANTATION
Nephrol Dial Transplant. 2014 Jul 25. pii: gfu252. [Epub ahead of print] Prediction of membranous nephropathy recurrence after transplantation by monitoring of anti-PLA2R1 (M-type phospholipase A2 receptor) autoantibodies: a case series of...

Duplication in Nephrology Publications

Written by Meguid El Nahas on Thursday, 28 August 2014. Posted in OLA Blog

Duplication in Nephrology Publications
SHARP Study GRoup.   The SHARP study group showed in their original publication that lipids lowering with a combination of simvastatin and ezetimibe had little effect on overall or cardiovascular mortality in CKD. They also showed that...

Short termism in Nephrology Publications...

Written by Meguid El Nahas on Thursday, 21 August 2014. Posted in OLA Blog

Short termism in Nephrology Publications...
It strikes that Nephrologists are so keen to publish theat they often publish short term, incomplete, underpowered and inaccurate informations...that shape our practice. Two recent examples, in ANCA associated systemic vasculitis (AASV): We wre...

PURE Confusion

Written by Meguid El Nahas on Friday, 15 August 2014. Posted in OLA Blog

PURE Confusion
Two articles have been published this month in the NEJM relating to the PURE study outcomes: N Engl J Med. 2014 Aug 14;371(7):601-11. doi: 10.1056/NEJMoa1311989.  and  N Engl J Med. 2014 Aug 14;371(7):612-23. doi:...

BE SMART ON SHARP!

Written by Meguid El Nahas on Friday, 15 August 2014. Posted in OLA Blog

BE SMART ON SHARP!
J Am Soc Nephrol. 2014 Aug;25(8):1825-33. doi: 10.1681/ASN.2013090965. Epub 2014 May 1.   This publication from the SHARP study group showed NO EFFECT of STATINS on the PROGRESSION OF CKD. COMMENTS: So the SHARP study is also...

NEPHROLOGY 40 YEARS ON: NIHILISTIC OR REALISTIC?

Written by Meguid El Nahas on Tuesday, 05 August 2014. Posted in OLA Blog

NEPHROLOGY 40 YEARS ON: NIHILISTIC OR REALISTIC?
I have been practicing Medicine and Nephrology for 40 years. It occured to me that true and major breakthroughs in the management of CKD have been few and far between during these 40-50 years. In fact, when I started practicing Nephrology and...

Alemtuzumab in transplantation - the 3C study

Written by arif khwaja on Friday, 01 August 2014. Posted in OLA Blog

Alemtuzumab in transplantation - the 3C study
The 3C study presented at this weeks’ World Transplant Congress and published online in the Lancet is an important study, which may in the future inform clinical practice in transplantation. In essence there are two parts to the study. The...

STEM CELL RESEARCH AND ETHICS

Written by Meguid El Nahas on Wednesday, 30 July 2014. Posted in OLA Blog

STEM CELL RESEARCH AND ETHICS
This month in the Lancet: An editorial by Farhat Yaqub on: Rana Dajani and teh Ethics of Stem cell Research in the Middle East. http://www.ncbi.nlm.nih.gov/pubmed/25066151 The editorial highlights Dr Rana Dajani elevated position in medical...

NICE NEW CKD GUIDELINES: A DAMP SQUIB?

Written by Meguid El Nahas on Wednesday, 30 July 2014. Posted in OLA Blog

NICE NEW CKD GUIDELINES: A DAMP SQUIB?
PROFESSOR RICHARD GLASSOCK WROTE: New NICE CKD Guidelines On July 23, 2014 the National Institute for Health and Care Excellence (NICE) of the United Kingdom released its new 2014 guidance for Chronic Kidney Disease (CKD). This new version...

mTOR inhibition and Anti-Phospholipid Syndrome

Written by arif khwaja on Thursday, 24 July 2014. Posted in OLA Blog

mTOR inhibition and Anti-Phospholipid Syndrome
High impact journals tend to focus on clinical trial data that are likely to impact on practice. So it was nice to see a very simple but elegant piece of ‘bench to bedside’ work published in this weeks’ NEJM from Canaud and...